Posted by Michael Wonder on 20 Aug 2020
Health Canada grants market authorization for Tecentriq in combination with bevacizumab, the first immunotherapy combination treatment, for the most common form of liver cancer
19 August 2020 - Tecentriq in combination with bevacizumab improved overall survival and progression-free survival compared to the previous standard of care.
Roche Canada today announced that Health Canada has granted market authorisation for Tecentriq (atezolizumab for injection), in combination with bevacizumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.
The Canadian authorisation was granted by Health Canada as a part of Project Orbis, an initiative of the FDA Oncology Center of Excellence which provides a framework for simultaneous submission and review of oncology products among international partners.
